Sabinsa secures a series of global patents for its growing portfolio

03-Mar-2014 - Last updated on 03-Mar-2014 at 16:08 GMT

Naturals ingredients players Sabinsa and its sister company Sami Labs have secured a number of country-specific patents for its portfolio of products, a number of which have skin care applications.

The company says that the move, which involves seven patents in Canada, New Zealand, Korea, the US and Europe, forms part of a strategy to protect the intellectual property of its growing portfolio on a global basis.

Thanks in part to the addition of the seven new patents, the India-based personal care and wellness players now has a portfolio of 87 products.

Working to protect the company’s intellectual property

"With 100 scientists continuing to research naturally derived herbal remedies to address common health concerns our patent portfolio is growing exponentially, so we have strengthened our legal teams accordingly to protect our IP," said Dr. Muhammed Majeed, chairman and founder of the Sami & Sabinsa group of companies.

"As we work to find safe and effective ways to keep the world's population healthier, ensuring that our patents are protected allows us to continue to invest in innovation. Our responding strongly to patent infringement protects the investment of our customers at the same time."

In New Zealand patent NZ598630 was issued for the proprietary Saberry and Cococin synergistic formulation and its protective effect on the dermal papilla cells. This technology has already been awarded the US Patent (US8247003).

Meanwhile, PteroWhite was awarded the DPR Korea Patent 1011504, which highlights the company’s research and development proving the ability of pterostilbene to modulate melanogenesis and skin hyper pigmentation.

Patents cover Asia Pacific, Europe and the US

In the US the company says that patent US8394852 has been awarded for the inotilone derivatives, which is the composition of matter. The invention delves into the synthetic routes for derivatives of 5-methyl-3(2H)-furanone compounds, compositions of matter and biological applications.

Also in the US, patent US8383594 was awarded for OLEPENT, an invention titled "Peptides modified with triterpenoids and small organic molecules: synthesis and use in cosmeceuticals" is specifically directed to a unique pentapeptide linked chemically to the plant derived Oleanolic acid and cosmetic compositions that focus on anti-aging.

In Europe patent EP1791423 was awarded for BOSWELLIN, which highlights the therapeutic potential of boswellic acids in combination with selenium amino acids to effectively manage inflammatory skin conditions of immunological origin like psoriasis.

The other two patents are for ophthalmic applications – in Hong Kong patent HK1098450 is for the technology behind Ocufors, while in Canada patent 2537820 was also registered under the Ocufors brand for a solubization method in ophthalmic therapies.